Human Immunodeficiency Virus Therapeutics Market Size, Share & Trends Report

Human Immunodeficiency Virus Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs), Non-NRTIs, Entry & Fusion, Protease), And Segment Forecasts, 2018 - 2025

Report ID: GVR-1-68038-210-5
Number of Pages: 75
Format: Electronic (PDF)

Historical Range: 2014 - 2015
Industry:Healthcare

Market Segmentation

Global HIV-1 Therapeutics Drug Class Outlook (USD Million, 2014 - 2025)
- Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
- Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
- Entry and Fusion Inhibitors
- Protease Inhibitors (PIs)
- Integrase Inhibitors
- Coreceptor Antagonists
Global HIV-1 Therapeutics Regional Outlook (USD Million, 2014 - 2025)
- North America
  - The U.S.
    - U.S.Drug Class Outlook (USD Million, 2014 - 2025)
    - Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
    - Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    - Entry and Fusion Inhibitors
    - Protease Inhibitors (PIs)
    - Integrase Inhibitors
    - Coreceptor Antagonists
  - Canada
    - Canada Drug Class Outlook (USD Million, 2014 - 2025)
    - Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
    - Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    - Entry and Fusion Inhibitors
    - Protease Inhibitors (PIs)
    - Integrase Inhibitors
    - Coreceptor Antagonists
- Europe
  - UK
    - UK Drug Classes Outlook (USD Million, 2014 - 2025)
    - Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
    - Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    - Entry and Fusion Inhibitors
    - Protease Inhibitors (PIs)
    - Integrase Inhibitors
    - Coreceptor Antagonists
  - Germany
    - Germany Drug Classes Outlook (USD Million, 2014 - 2025)
    - Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
    - Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    - Entry and Fusion Inhibitors
    - Protease Inhibitors (PIs)
    - Integrase Inhibitors
    - Coreceptor Antagonists
- Asia Pacific
  - Japan
    - Japan Drug Classes Outlook (USD Million, 2014 - 2025)
    - Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
    - Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    - Entry and Fusion Inhibitors
    - Protease Inhibitors (PIs)
    - Integrase Inhibitors
    - Coreceptor Antagonists
  - China
    - China Drug Classes Outlook (USD Million, 2014 - 2025)
    - Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
    - Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    - Entry and Fusion Inhibitors
    - Protease Inhibitors (PIs)
    - Integrase Inhibitors
    - Coreceptor Antagonists
  - India
    - India Drug Classes Outlook (USD Million, 2014 - 2025)
    - Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
    - Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    - Entry and Fusion Inhibitors
    - Protease Inhibitors (PIs)
    - Integrase Inhibitors
    - Coreceptor Antagonists
- Latin America
  - Mexico
    - Mexico Drug Classes Outlook (USD Million, 2014 - 2025)
    - Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
    - Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    - Entry and Fusion Inhibitors
    - Protease Inhibitors (PIs)
    - Integrase Inhibitors
    - Coreceptor Antagonists
  - Brazil
    - Brazil Drug Classes Outlook (USD Million, 2014 - 2025)
    - Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
    - Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    - Entry and Fusion Inhibitors
    - Protease Inhibitors (PIs)
    - Integrase Inhibitors
    - Coreceptor Antagonists
- MEA
  - South Africa
    - South Africa Drug Classes Outlook (USD Million, 2014 - 2025)
    - Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
    - Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    - Entry and Fusion Inhibitors
    - Protease Inhibitors (PIs)
    - Integrase Inhibitors
    - Coreceptor Antagonists

GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

Or view our licence options:

NEED A CUSTOM REPORT?

We can customize every report -free of charge- including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

ESOMAR certified & member

Leading SME award by D&B

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read ourprivacy policy.